Cardiometabolic Health Benefits Uncovered With GLP-1 Therapy

GLP-1 therapy plays a vital role in cardiometabolic health; UNDERSTANDING its significance and benefits for your body.

Unlocking Better Patient Outcomes: The Role of GLP-1 Agonists in Modern Diabetes and Metabolic Care

As an integrative healthcare practitioner with the titles DC, APRN, FNP-BC, CFMP, IFMCP, ATN, and CCST, I am deeply committed to an integrative and evidence-based approach to patient care. My clinical observations at the Sciatica Clinic have consistently shown that a holistic approach addressing the root causes of disease yields the most sustainable and profound results. Today, I want to share some transformative insights into a class of medications reshaping how we approach type 2 diabetes, obesity, and even cardiovascular health: GLP-1 receptor agonists. This post reflects the latest findings from leading researchers and presents them in practical, easy-to-understand terms. We will explore the powerful role of these medications in transforming patient outcomes, not just by lowering blood sugar, but by addressing the interconnected web of cardiovascular, renal, and metabolic health, and how they fit into a holistic treatment paradigm that includes foundational elements like chiropractic care.

Abstract

This educational post explores the multifaceted role of Glucagon-Like Peptide-1 (GLP-1) receptor agonists in managing patients with type 2 diabetes and associated metabolic disorders. As your author, Dr. Jimenez, I will guide you through the latest evidence-based research, starting with an overview of the significant cardiovascular risks faced by individuals with diabetes and the shift toward a comprehensive risk-reduction model. We will delve into the physiological mechanisms underlying the incretin effect and how drugs such as Semaglutide, liraglutide, and the dual-agonist tirzepatide influence appetite, insulin secretion, and gastric emptying. I will present data from major cardiovascular outcomes trials (CVOTs) that demonstrate these agents offer robust heart and kidney protection. We will discuss practical applications, including a clinical case study, switching between agents, and managing side effects. The expanding investigational uses in areas like liver disease, neuroprotection, and addiction will be examined. Finally, I will discuss how integrative chiropractic care complements this biomedical approach by addressing the foundational aspects of lifestyle, nervous system function, and musculoskeletal health, creating a truly holistic treatment plan.

The Shifting Paradigm in Diabetes Management

For years, the primary focus in managing type 2 diabetes was on a single metric: blood glucose. While controlling blood sugar is crucial, we now understand that this approach is far too narrow. Patients with diabetes face a dramatically elevated risk for arteriosclerotic cardiovascular disease (ASCVD), a group of conditions that includes coronary heart disease, stroke, and peripheral arterial disease. In fact, ASCVD is the leading cause of death for people with type 2 diabetes.

Consider these sobering facts from leading research (American Diabetes Association, 2024):

• Over 70% of elderly individuals with diabetes are likely to die from heart disease or stroke.
• Following a heart attack (myocardial infarction or MI), people with diabetes have a much higher risk of death and face a poorer long-term prognosis compared to those without diabetes.
• These grim outcomes often persist even when a patient’s blood sugar is considered “well-controlled.”

This evidence has led us to update our treatment philosophy. The conversation has shifted from a glucose-centric model to a comprehensive, multifaceted management plan.

Embracing a Collaborative and Holistic Approach

Today, a collaborative approach is the gold standard. Major health organizations, including the American College of Cardiology (ACC), the American Heart Association (AHA), the American Diabetes Association (ADA), and the Kidney Disease Improving Global Outcomes (KDIGO) group, are all in agreement. We must move beyond simply lowering glucose and aim to reduce overall risk factors.

The pillars of modern management for individuals with diabetes, as outlined by the American Diabetes Association (2024), include:

• Lifestyle Management: This forms the foundation, encompassing nutrition, physical activity, and diabetes self-management education.
• Cardiovascular Disease (CVD) Risk Management: This involves aggressively managing:

• • Blood pressure
  • Cholesterol and lipids
  • Blood glucose
  • Body weight

• Smoking Cessation: A non-negotiable component for reducing cardiovascular risk.

From my integrative perspective, this is where a truly holistic model shines. While we use advanced pharmacology to target specific physiological pathways, we must never lose sight of the foundational elements. This is where integrative chiropractic care becomes an essential partner. By focusing on optimizing nervous system function through spinal adjustments, addressing musculoskeletal imbalances that may limit physical activity, and providing detailed lifestyle and nutritional counseling, we support the very pillars upon which these medical interventions are built. In my clinical experience at our clinics, patients who receive this integrated support are more successful in implementing and sustaining the lifestyle changes that support long-term health.

A Clinical Case Study: Introducing Naomi

To illustrate these concepts, let’s consider a common clinical scenario. “Naomi” is a 66-year-old female who has lived with type 2 diabetes for over 12 years.

• Her A1c is 8.3%, well above the target goal of less than 7%.
• She has several comorbidities: hypertension, high cholesterol (dyslipidemia), and protein in her urine (proteinuria), indicating kidney stress.
• Her medications include metformin, a statin for cholesterol, an ARB for blood pressure, an SGLT2 inhibitor (another class of diabetes medication), and a significant dose of basal insulin (66 units of degludec daily).
• Despite this regimen, her morning fasting glucose levels remain high, ranging from 140-160 mg/dL (the goal is 90-130 mg/dL).
• Her weight is 220 pounds (100 kg), with a BMI of 32.5, placing her in the obese category.

The Problem of “Over-Basalization”

A key issue for Naomi is that she is over-basalized. This means she is on a very high dose of basal (long-acting) insulin, yet her glucose control remains poor. A simple clinical calculation helps identify this: we multiply the patient’s weight in kilograms by approximately 0.5. For Naomi, at 100 kg, any dose of basal insulin above 50 units can be considered over-basalization. She is taking 66 units and is still not at her goal.

Furthermore, her primary issue appears to be postprandial hyperglycemia—spikes in blood sugar after meals. The traditional next step might be to add prandial (mealtime) insulin. However, this adds complexity, increases the risk of hypoglycemia (low blood sugar), and often contributes to further weight gain. This is where a more strategic approach is needed.

The Science of Satiety: The Incretin Effect

To truly appreciate how these medications work, we must understand a key physiological process called the “incretin effect”. This term refers to the body’s natural hormonal response to food. When you eat, and food enters your gastrointestinal (GI) tract, specialized cells in your intestine (L-cells) release hormones, primarily GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). This release is glucose-dependent, meaning it occurs in response to food ingestion rather than to intravenously administered glucose. These incretin hormones then travel to the pancreas, signaling it to increase insulin secretion and prepare the body to manage the glucose from the meal you just consumed.

In individuals with type 2 diabetes, this natural incretin effect is often blunted or even absent. Their bodies produce insufficient amounts of GLP-1, leading to poor insulin secretion after meals and a failure to suppress glucagon, a hormone that raises blood sugar. The GLP-1 receptor agonist medications are designed to mimic or enhance this natural process, effectively restoring this vital signaling pathway.

Mechanisms of Action: A Multi-System Approach

Before initiating mealtime insulin, the ideal intervention for a patient like Naomi is a GLP-1 receptor agonist. These medications orchestrate a symphony of metabolic changes throughout the body by mimicking the action of the natural GLP-1 hormone, but for a much longer duration.

1. Glucose-Dependent Insulin Secretion: They stimulate the pancreas to release insulin, but only when blood sugar is high. This smart mechanism significantly reduces the risk of hypoglycemia compared to insulin.
2. Suppression of Glucagon: They reduce the secretion of glucagon, a hormone that tells the liver to release stored sugar. Suppressing glucagon is vital because, in type 2 diabetes, the body often inappropriately releases stored glucose even when blood sugar is already high. This helps lower both fasting and post-meal glucose levels.
3. Delayed Gastric Emptying: It slows how quickly food leaves the stomach. Food remains in the stomach for a longer period, which contributes significantly to a feeling of fullness, or satiety. This helps reduce overall food intake, supports weight loss, and blunts the sharp spike in blood sugar after a meal. This same mechanism, however, can cause side effects like mild nausea or discomfort, particularly when starting the medication.
4. Central Appetite Regulation: We believe these small-molecule drugs can cross the blood-brain barrier and act directly on the hypothalamus, the brain’s appetite control center. This central action helps to decrease appetite and reduce food cravings, providing another powerful tool for weight management.

Dr. Ralph DeFronzo’s famous “ominous octet” paper from 2009 outlined eight core pathophysiological defects in type 2 diabetes. Remarkably, GLP-1 receptor agonists address six of these eight defects, making them one of the most comprehensive therapies available (DeFronzo, 2009).

Understanding the Power of GLP-1 Agonists: A Comparison

The development of GLP-1 receptor agonists has been a game-changer, and with each new agent, the benefits become more profound. Let’s look at the data from leading researchers to understand this progression in A1c reduction and weight loss:

• Exenatide (2005): ~0.9% A1c reduction; ~2.9 kg weight loss.
• Liraglutide (2010): ~1.1% A1c reduction; ~2.5 kg weight loss.
• Dulaglutide: Demonstrated an average weight loss of 4.6 kilograms and an A1c reduction of over 1.5%.
• Semaglutide: Pushes the boundaries further, showing an average weight loss of 6.4 kilograms and a more robust A1c reduction of 1.8% to 2.1%.
• Tirzepatide: As a dual GIP/GLP-1 receptor agonist (“twincretin”), tirzepatide has set a new benchmark. Clinical trials revealed a staggering 11.2 kilograms of weight loss—almost double that of Semaglutide—and a significant 2.3% reduction in A1c (Frias et al., 2021).

For a patient like Naomi, who has established cardiovascular risk factors and needs significant improvement in both A1c and weight, an agent with proven MACE reduction and robust weight loss effects, such as Semaglutide or tirzepatide, would be an excellent evidence-based choice.

Medication (Brand Name)	Primary Indication(s)	Proven Benefits in FDA Label
Semaglutide (Ozempic/Rybelsus)	Type 2 Diabetes	MACE Reduction, Nephropathy Protection
Semaglutide (Wegovy)	Weight Loss	MACE Reduction
Liraglutide (Victoza)	Type 2 Diabetes	MACE Reduction, Nephropathy Protection
Dulaglutide (Trulicity)	Type 2 Diabetes	MACE Reduction, Nephropathy Protection
Tirzepatide (Mounjaro/Zepbound)	Type 2 Diabetes, Weight Loss, Obstructive Sleep Apnea (OSA)	Dual GLP-1/GIP agonist (“twincretin”) with superior A1c and weight loss effects.
Exenatide (Byetta)	Type 2 Diabetes	No specific CVD or renal benefit is listed on the label.

The CVOT Revolution: Protecting the Heart and Kidneys

The American Diabetes Association (ADA) guidelines have evolved dramatically in response to the overwhelming evidence supporting these medications. The 2024 guidelines prioritize treatment based on a patient’s comorbidities, especially cardiovascular and kidney health (ElSayed et al., 2024). This shift was driven by a series of landmark studies known as Cardiovascular Outcomes Trials (CVOTs). In 2008, the FDA mandated that all new diabetes drugs must prove they do not cause cardiovascular harm. What happened next was revolutionary: these drugs were found to significantly reduce cardiovascular events.

• The LEADER Trial: Studied liraglutide and showed a 13% reduction in major adverse cardiovascular events (MACE) (Marso et al., 2016).
• The SUSTAIN-6 Trial: Focused on Semaglutide and demonstrated a remarkable 26% reduction in MACE (Marso et al., 2016).
• The REWIND Trial: Evaluated dulaglutide and showed a 12% reduction in MACE (Gerstein et al., 2019).
• The SELECT Trial: This groundbreaking trial studied overweight or obese patients with heart disease. Semaglutide reduced the risk of MACE by 20%, establishing it as a cardiovascular drug independent of blood sugar effects (Lincoff et al., 2023).
• The FLOW Trial: This study on Semaglutide was stopped early in October 2023 because it showed an overwhelming 24% reduction in the risk of kidney disease progression and death from related causes, leading to a new nephropathy indication for Semaglutide in 2024.

These were massive, double-masked, placebo-controlled studies that ran for years. The results were undeniable and changed the standard of care. We could no longer think of these as “just diabetes drugs.” They are cardiovascular and renal-protective agents.

---

Balancing Body and Metabolism- Video

---

Navigating Treatment: How to Switch Between GLP-1 Medications

One of the most common clinical questions is how to switch between GLP-1 medications if a patient isn’t achieving desired results. Let’s consider a patient, “Tammy,” on Trulicity (dulaglutide) 1.5 mg weekly, who is struggling to lose weight and has heard about the success of Ozempic (Semaglutide) or Mounjaro (tirzepatide).

• Option 1: Maximize the Current Medication. We could titrate her Trulicity dose up to its maximum of 4.5 mg weekly.
• Option 2: Switch to a Different GLP-1 Agent. This is a very reasonable, patient-centered path.

Switching Protocol: A Practical Guide

While no official guidelines exist, clinical experience provides a safe approach. The goal is to find the minimum effective dose that provides the satiety signal without intolerable side effects.

• Switching to Semaglutide (Ozempic): After Tammy’s last Trulicity dose, we would wait one week. To minimize GI side effects, I would start her on a weekly dose of 0.5 mg for 4 weeks before considering an increase to 1.0 mg.
• Switching to Tirzepatide (Mounjaro): After her last Trulicity dose, we would wait one week and start her on the 5 mg weekly dose. This is a safe and effective starting point that can be titrated up as needed to 7.5 mg, 10 mg, 12.5 mg, or the maximum of 15 mg.

Navigating Side Effects and Safety

While the benefits are immense, it’s my duty as a clinician to ensure patients use these medications safely.

• GI Side Effects: Nausea is the most common. In my practice, I emphasize a “start low, go slow” approach, often keeping patients on the lowest dose for at least a month. I also provide crucial dietary counseling: avoid large, high-fat, or high-carb meals.
• Serious Risks: Though rare, acute kidney injury can occur if vomiting leads to dehydration. Pancreatitis has been reported. Patients with a history of severe gastroparesis or bowel obstructions are generally not good candidates.
• Black Box Warning: All GLP-1 agonists carry a black box warning for the risk of thyroid C-cell tumors (medullary thyroid carcinoma), which was observed in rodents. These drugs are contraindicated in anyone with a personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Anesthesia Concerns: The slowed gastric emptying poses a risk of aspiration during surgery. Anesthesia societies now recommend stopping weekly GLP-1 agonists at least one to two weeks before a planned procedure.

The Expanding Universe of GLP-1s: Investigational Uses

The story of GLP-1s is no longer just about diabetes and weight loss. Researchers are uncovering benefits across various body systems.

• Metabolically Associated Steatotic Liver Disease (MASLD, formerly NAFLD) and MASH: We believe the primary benefit is related to the significant and sustained weight loss these drugs produce, which reduces fat stored in the liver. Novo Nordisk is actively seeking an FDA indication for Semaglutide in the treatment of MASH, with approval anticipated for late 2025 or early 2026.
• Neuropsychiatric and Neuroprotective Effects: There are signs of a powerful neuroprotective effect, with observations of stalled dementia progression and improved Parkinson’s symptoms. This may be due to GLP-1 molecules crossing the blood-brain barrier and exerting anti-inflammatory actions.
• Addiction and Compulsive Behaviors: A fascinating observation from my patients is a reduction in cravings for food, alcohol, and nicotine. It seems these drugs dampen the brain’s craving and reward pathways.
• PCOS, Fertility, and “Ozempic Babies”: We’ve seen significant improvements in Polycystic Ovary Syndrome (PCOS) and fertility, likely due to metabolic improvements and weight loss. This has led to stories of “Ozempic babies”—women who conceived while taking the medication.
• Latent Autoimmune Diabetes in Adults (LADA): The thinking is that using a GLP-1 agonist (off-label) may help preserve remaining pancreatic beta cells in this slow-progressing form of type 1 diabetes by reducing metabolic stress.

The Role of Integrative Chiropractic Care in a New Era of Medicine

I often say that I can no longer claim these as just “diabetes drugs.” I have to share them with my cardiology and nephrology colleagues. We are not treating isolated conditions; we are treating the metabolic-cardiovascular-renal triad. This is where a truly integrative approach becomes essential.

How Chiropractic Care Complements GLP-1 Therapy

1. Addressing Musculoskeletal Health and Inflammation: As a Doctor of Chiropractic, my role is to ensure that a patient’s musculoskeletal system functions optimally as they increase physical activity. By addressing spinal misalignments (subluxations) and improving joint mobility through chiropractic adjustments, we help patients exercise comfortably and without injury. Chronic pain and inflammation can raise cortisol levels, which can disrupt blood sugar and counteract the effects of GLP-1s.
2. Nutritional Counseling and Lifestyle Coaching: As a Certified Functional Medicine Practitioner (CFMP), I provide personalized nutritional guidance that complements the effects of GLP-1s. We focus on nutrient-dense, anti-inflammatory foods, stress management, and sleep hygiene—all crucial for long-term success.
3. Enhancing Cellular Function and Reducing Oxidative Stress: Functional medicine protocols can support mitochondrial health and improve cellular insulin sensitivity. This holistic strategy ensures we are not just masking symptoms but are truly healing the body from the inside out. My clinical experience at our clinic has shown that patients who combine GLP-1 therapy with our comprehensive integrative care plan report better outcomes, including weight loss, improved energy, and reduced pain.

By combining the latest in evidence-based medicine with foundational care that supports the body’s structure and function, we can truly empower our patients to achieve lasting metabolic health and well-being.

References

• American Diabetes Association. (2024). Standards of care in diabetes—2024. Diabetes Care, 47(Supplement_1).
• DeFronzo, R. A. (2009). From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. Diabetes, 58(4), 773–795. https://doi.org/10.2337/db09-9028
• ElSayed, N. A., Dungan, K. M., & Gabbay, R. A. (2024). 9. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes—2024. Diabetes Care, 47(Supplement_1), S158–S178. https://doi.org/10.2337/dc24-S009
• Frias, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021). Tirzepatide versus Semaglutide once weekly in patients with type 2 diabetes. The New England Journal of Medicine, 385(6), 503–515.
• Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., Xavier, D., Atisso, C. M., Dyal, L., Hall, S., Rao-Melacini, P., Wong, G., & Avezum, A. (2019). Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomized placebo-controlled trial. The Lancet, 394(10193), 121–130. https://doi.org/10.1016/s0140-6736(19)31149-3
• Jimenez, A. (n.d.). Clinical Observations. Sciatica.clinic. Retrieved May 21, 2026, from https://sciatica.clinic/
• Jimenez, A. (n.d.). Dr. Alex Jimenez. LinkedIn. Retrieved May 21, 2026, from https://www.linkedin.com/in/dralexjimenez/
• Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Tarp-Johansen, M. J., & Thorn, G. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221–2232. https://doi.org/10.1056/nejmoa2307563
• Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., Vilsbøll, T., & Hansen, T. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 375(19), 1834–1844. https://doi.org/10.1056/nejmoa1607141
• Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., Steinberg, W. M., Stockner, M., & Zinman, B. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 375(4), 311–322. https://doi.org/10.1056/nejmoa1603827

Note: The discussion of specific medications, dosages, and off-label uses is for educational purposes only and does not constitute medical advice. Treatment decisions should always be made in consultation with a qualified healthcare provider.

SEO Tags: GLP-1 agonists, type 2 diabetes, integrative chiropractic care, Dr. Alex Jimenez, cardiovascular risk reduction, weight loss, Mounjaro, Ozempic, Semaglutide, tirzepatide, A1c, postprandial glucose, functional medicine, holistic health, diabetes management, metabolic health, ASCVD, MACE reduction, incretin effect, over-basalization, evidence-based medicine, Semaglutide, Wegovy, Cardiovascular Outcomes, Satiety, Gastric Emptying, CVOT, LEADER Trial, SUSTAIN-6 Trial, SELECT Trial, El Paso TX, Heart Health, Kidney Disease, renal health, neuroprotection, PCOS, LADA, patient-centered care, chiropractic adjustments, lifestyle medicine, MASLD, MASH